Pawlik, B.; Smyczyńska, U.; Grabia, S.; Fendler, W.; Dróżdż, I.; Bąbol-Pokora, K.; Kotulska, K.; Jóźwiak, S.; Borkowska, J.; Młynarski, W.;
et al. mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile. J. Clin. Med. 2022, 11, 3395.
https://doi.org/10.3390/jcm11123395
AMA Style
Pawlik B, Smyczyńska U, Grabia S, Fendler W, Dróżdż I, Bąbol-Pokora K, Kotulska K, Jóźwiak S, Borkowska J, Młynarski W,
et al. mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile. Journal of Clinical Medicine. 2022; 11(12):3395.
https://doi.org/10.3390/jcm11123395
Chicago/Turabian Style
Pawlik, Bartłomiej, Urszula Smyczyńska, Szymon Grabia, Wojciech Fendler, Izabela Dróżdż, Katarzyna Bąbol-Pokora, Katarzyna Kotulska, Sergiusz Jóźwiak, Julita Borkowska, Wojciech Młynarski,
and et al. 2022. "mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile" Journal of Clinical Medicine 11, no. 12: 3395.
https://doi.org/10.3390/jcm11123395
APA Style
Pawlik, B., Smyczyńska, U., Grabia, S., Fendler, W., Dróżdż, I., Bąbol-Pokora, K., Kotulska, K., Jóźwiak, S., Borkowska, J., Młynarski, W., & Trelińska, J.
(2022). mTOR Inhibitor Treatment in Patients with Tuberous Sclerosis Complex Is Associated with Specific Changes in microRNA Serum Profile. Journal of Clinical Medicine, 11(12), 3395.
https://doi.org/10.3390/jcm11123395